

# Budenofalk granules and capsules in the treatment of Crohn's disease

Gepubliceerd: 05-08-2016 Laatste bijgewerkt: 18-08-2022

The purpose of this observational study is to obtain insight into the treatment of the acute phase of Crohn's disease with Budenofalk® 9 mg granules and 3 mg capsules among outpatients attending regular gastroenterological practice. Likely,...

<b>Ethische beoordeling</b>	Niet van toepassing
<b>Status</b>	Werving nog niet gestart
<b>Type aandoening</b>	-
<b>Onderzoekstype</b>	Observationeel onderzoek, zonder invasieve metingen

## Samenvatting

### ID

NL-OMON24660

### Bron

NTR

### Verkorte titel

BALANCE

### Aandoening

Crohn's disease, budesonide, Budenofalk, IBD, ziekte van Crohn

### Ondersteuning

**Primaire sponsor:** Dr. Falk Pharma Benelux B.V.

**Overige ondersteuning:** Dr. Falk Pharma Benelux B.V.

### Onderzoeksproduct en/of interventie

### Uitkomstmaten

#### Primaire uitkomstmaten

The objective of this study is to obtain an insight into the treatment of acute Crohn's disease with Budenofalk 9 mg granules and 3 mg capsules among outpatients attending regular

gastroenterological practice. The primary outcome is the percentage of physicians who perform Budenofalk therapy as described in the SPC.

## Toelichting onderzoek

### Achtergrond van het onderzoek

European guidelines recommend 9 mg budesonide daily as the preferred initial therapy for mild to

moderate active Crohn's disease localized at the ileocecal region. Existing guidelines do not provide

suggestions for the treatment schedule or duration, however. Though the SPCs for Budenofalk®

granules and Budenofalk® capsules provide guidance, treatment schedules using these agents are

generally formed by the treating physician in a case-by-case manner. Studies looking into the use of

Budenofalk® in this setting have not previously been performed. Likely, different dosing schedules and

treatment durations are employed for the induction of remission in Crohn's disease patients in clinical

practice. We expect these differences could have an effect on several levels; e.g. therapeutic adherence, success of therapy, patient experience, and drug tolerability.

This study has been developed to assess the use of Budenofalk® in the treatment of acute Crohn's disease in routine clinical practice We aim to assess how Budenofalk® is used; at which dose

and for how long, and how the observed differences impact the patient. Results obtained in this study

will help to improve the management of Crohn's disease.

Approximately 150 adult patients, both male and female, with endoscopically determined

Crohn's disease will be included. In accordance with the SPC, patients must be over 18 years of age at

the start of the therapy. The patients will belong to the regular outpatient population of the participating physicians. They will be included in the study after an initial disease diagnosis or the diagnosis of a new flare has been made and the treating physician has decided to prescribe Budenofalk® 9 mg granules or 3 mg capsules. The prospective investigation will be carried out throughout the Netherlands.

### **Doel van het onderzoek**

The purpose of this observational study is to obtain insight into the treatment of the acute phase of Crohn's disease with Budenofalk® 9 mg granules and 3 mg capsules among outpatients attending regular gastroenterological practice. Likely, different dosing schedules and treatment durations are employed for the induction of remission. We aim to discover how these differences affect therapeutic adherence, success of therapy, patient experience, and drug tolerability.

### **Onderzoeksopzet**

Treatment duration for each patient will be decided on by the treating physician and study visits will align with the regular consultations. The study will therefore include the initial consultation (day 0 of treatment), a follow up consultation after 2 - 5 weeks, a final consultation at the end of the therapy (i.e. after 6 - 10 weeks) and a follow up safety assessment (4 weeks post last treatment dose).

### **Onderzoeksproduct en/of interventie**

None. This is a prospective, multicenter, observational study. This means that intervention is not the purpose of this study; patients will be treated solely as part of regular medical therapy. Therapeutic necessity will be the only determinant of selection of the medicine.

## **Contactpersonen**

### **Publiek**

Dr. Falk Pharma Benelux B.V.

C. Koks  
Claudius Prinsenlaan 136A

Breda 4818 CP  
The Netherlands  
tel. 076 - 524 42 00

## **Wetenschappelijk**

Dr. Falk Pharma Benelux B.V.

C. Koks  
Claudius Prinsenlaan 136A

Breda 4818 CP  
The Netherlands  
tel. 076 - 524 42 00

## **Deelname eisen**

### **Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)**

age > 18 years;

seen in the outpatient department;  
have been prescribed Budenofalk granules or capsules for the treatment of mild to moderate active Crohn's disease;

have received adequate information regarding this observational study and have voluntarily agreed to the use of their data

### **Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)**

have severe active Crohn's disease;

are being treated with corticosteroids for current flare;

are hypersensitive to the active substance or any of the excipients;

are enrolled and involved in an interventional study

## Onderzoeksopzet

### Opzet

Type:	Observationeel onderzoek, zonder invasieve metingen
Onderzoeksmodel:	Anders
Blinding:	Open / niet geblindeerd
Controle:	N.v.t. / onbekend

### Deelname

Nederland	
Status:	Werving nog niet gestart
(Verwachte) startdatum:	01-11-2016
Aantal proefpersonen:	138
Type:	Verwachte startdatum

## Ethische beoordeling

Niet van toepassing	
Soort:	Niet van toepassing

## Registraties

### Opgevolgd door onderstaande (mogelijk meer actuele) registratie

Geen registraties gevonden.

### Andere (mogelijk minder actuele) registraties in dit register

Geen registraties gevonden.

### In overige registers

**Register**

NTR-new

NTR-old

Ander register

**ID**

NL5842

NTR5997

Dr. Falk Pharma Benelux B.V. : BUG-004CDA

## Resultaten